Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial ...

AI drug creation company Absci Corporation (NASDAQ:ABSI) shares are trading higher in premarket on Wednesday after the ...

The $20 million deal gives the chip supplier a toehold in the life-sciences market, a strategy it plans to replicate in other ...

Absci will use AMD’s $20 million investment to enhance its AI models. In parallel, the companies will collaborate to develop ...

Analyst Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on AbSci (ABSI – Research Report) and keeping the price target at ...

Absci (NASDAQ:ABSI – Free Report) had its price objective cut by KeyCorp from $6.00 to $5.00 in a research note released on Wednesday,Benzinga reports. They currently have an overweight rating on the ...

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...

Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.

Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to ...

Absci has a 52-week low of $2.45 and a 52-week high of $6.72. The firm has a market capitalization of $369.84 million, a price-to-earnings ratio of -3.46 and a beta of 2.04.

Following HSBC downgrading of the semiconductor company's stock, Advanced Micro Devices ( AMD, Financials) shares fell over 5 ...

Chip designer AMD said Wednesday that it will invest $20 million in Absci, the Vancouver company that aims to use artificial intelligence to develop new drug therapies. Absci hopes artificial ...